Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: PROTEIN KINASE INHIBITORS - THERAPEUTIC USE , . Treffer: 21
2021
Eichler, M; Pink, D; Menge, F; Jakob, J; Hentschel, L; Richter, S; Hohenberger, P; Kasper, B; Andreou, D; Singer, S; Grützmann, R; Dmytrow, DI; Arndt, K; Tuchscherer, A; Reichardt, P; Ahrens, M; Kunitz, A; Mohm, J; Bornhäuser, M; Schmitt, J; Schuler, MK
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa).
Eur J Cancer Care (Engl). 2021; 30(6):e13484
Doi: 10.1111/ecc.13484
Web of Science
PubMed
FullText
FullText_MUG
2019
Jilg, S; Rassner, M; Maier, J; Waldeck, S; Kehl, V; Follo, M; Philipp, U; Sauter, A; Specht, K; Mitschke, J; Lange, T; Bauer, S; Jost, PJ; Peschel, C; Duyster, J; Gaiser, T; Hohenberger, P; von Bubnoff, N
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Int J Cancer. 2019; 145(8):2292-2303
Doi: 10.1002/ijc.32282
Web of Science
PubMed
FullText
FullText_MUG
Riedmann, K; Bassermann, F; Jost, PJ
[Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544
Doi: 10.1007/s00108-019-0577-8
Web of Science
PubMed
FullText
FullText_MUG
2017
Byrgazov, K; Kastner, R; Gorna, M; Hoermann, G; Koenig, M; Lucini, CB; Ulreich, R; Benesch, M; Strenger, V; Lackner, H; Schwinger, W; Sovinz, P; Haas, OA; van den Heuvel-Eibrink, M; Niemeyer, CM; Hantschel, O; Valent, P; Superti-Furga, G; Urban, C; Dworzak, MN; Lion, T
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.
Leukemia. 2017; 31(1):237-240
Doi: 10.1038/leu.2016.250
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303
Doi: 10.1007/s13277-015-4543-3
Web of Science
PubMed
FullText
FullText_MUG
Mir, O; Brodowicz, T; Italiano, A; Wallet, J; Blay, JY; Bertucci, F; Chevreau, C; Piperno-Neumann, S; Bompas, E; Salas, S; Perrin, C; Delcambre, C; Liegl-Atzwanger, B; Toulmonde, M; Dumont, S; Ray-Coquard, I; Clisant, S; Taieb, S; Guillemet, C; Rios, M; Collard, O; Bozec, L; Cupissol, D; Saada-Bouzid, E; Lemaignan, C; Eisterer, W; Isambert, N; Chaigneau, L; Cesne, AL; Penel, N
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2016; 17(12):1732-1742
Doi: 10.1016/S1470-2045(16)30507-1
Web of Science
PubMed
FullText
FullText_MUG
Rainer, PP; Kass, DA
Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.
Cardiovasc Res. 2016; 111(2):154-162
Doi: 10.1093/cvr/cvw107
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Hoffmann, K; Ganten, T; Gotthardtp, D; Radeleff, B; Settmacher, U; Kollmar, O; Nadalin, S; Karapanagiotou-Schenkel, I; von Kalle, C; Jäger, D; Büchler, MW; Schemmer, P
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
BMC Cancer. 2015; 15(11):392-392
Doi: 10.1186/s12885-015-1373-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Obenauf, AC; Zou, Y; Ji, AL; Vanharanta, S; Shu, W; Shi, H; Kong, X; Bosenberg, MC; Wiesner, T; Rosen, N; Lo, RS; Massagué, J
Therapy-induced tumour secretomes promote resistance and tumour progression.
Nature. 2015; 520(7547): 368-372.
Doi: 10.1038/nature14336
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Aigner, B; Ugurel, S; Kaddu, S; Becker, JC
[Cutaneous sarcomas: update on selected fibrohistiocytic and myofibroblastic tumors].
Hautarzt. 2014; 65(7):614-622
Doi: 10.1007/s00105-013-2738-3
Web of Science
PubMed
FullText
FullText_MUG
Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203
Doi: 10.1136/jclinpath-2013-201904
Web of Science
PubMed
FullText
FullText_MUG
Ugurel, S; Mentzel, T; Utikal, J; Helmbold, P; Mohr, P; Pföhler, C; Schiller, M; Hauschild, A; Hein, R; Kämpgen, E; Kellner, I; Leverkus, M; Becker, JC; Ströbel, P; Schadendorf, D
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Clin Cancer Res. 2014; 20(2):499-510
Doi: 10.1158/1078-0432.CCR-13-1411
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2012
Flaherty, KT; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, LV; Hassel, JC; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, JMG; Utikal, J; Dreno, B; Nyakas, M; Middleton, MR; Becker, JC; Casey, M; Sherman, LJ; Wu, FS; Ouellet, D; Martin, AM; Patel, K; Schadendorf, D;
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma.
N ENGL J MED. 2012; 367(2): 107-114.
Doi: 10.1056/NEJMoa1203421
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A
Cutaneous side effects of new antitumor drugs: clinical features and management.
Dtsch Arztebl Int. 2012; 109(8):133-140
Doi: 10.3238/arztebl.2012.0133
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Valent, P; Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Wolf, D
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Crit Rev Oncol Hematol. 2012; 82(3):370-377
Doi: 10.1016/j.critrevonc.2011.08.002
Web of Science
PubMed
FullText
FullText_MUG
2011
Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F; und die Arbeitsgruppe Pulmopathologie der ÖGP-IAP
Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer.
Wien Klin Wochenschr. 2011; 123(9-10):316-321
Doi: 10.1007/s00508-011-1573-8
Web of Science
PubMed
FullText
FullText_MUG
2010
Pircher, A; Ploner, F; Popper, H; Hilbe, W
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Lung Cancer. 2010; 69(3): 265-271.
Doi: 10.1016/j.lungcan.2010.01.017
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2009
Benesch, M; Wardelmann, E; Ferrari, A; Brennan, B; Verschuur, A
Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature.
PEDIATR BLOOD CANCER. 2009; 53(7): 1171-1179.
Doi: 10.1002/pbc.22123
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2008
Liegl, B; Kepten, I; Le, C; Zhu, M; Demetri, GD; Heinrich, MC; Fletcher, CD; Corless, CL; Fletcher, JA
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
J Pathol. 2008; 216(1): 64-74.
Doi: 10.1002/path.2382
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2007
Ugurel, S
Targeted therapy of dermatofibrosarcoma with imatinib.
J Dtsch Dermatol Ges. 2007; 5(3):261-261
Doi: 10.1111/j.1610-0387.2007.07009.x
PubMed
FullText
FullText_MUG
Utikal, J; Ugurel, S; Kurzen, H; Erben, P; Reiter, A; Hochhaus, A; Nebe, T; Hildenbrand, R; Haberkorn, U; Goerdt, S; Schadendorf, D
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Arch Dermatol. 2007; 143(6):736-740
Doi: 10.1001/archderm.143.6.736
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar